Thymogen
A synthetic Glu-Trp dipeptide bioregulator that targets thymus-dependent cellular immunity and T-cell function.
Thymogen is a synthetic dipeptide (glutamyl-tryptophan, Glu-Trp) developed at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson. Identified as an active short-peptide component of the calf-thymus extract Thymalin, it was synthesized as a defined compound to support thymus-dependent immunity. Registered as a pharmaceutical in Russia since the late 1980s for cellular immunodeficiency states, it remains an unapproved research peptide in Western jurisdictions with moderate Russian and limited Western supporting evidence.
Class
Synthetic dipeptide immunomodulator (Khavinson short-peptide bioregulator)
Half-life
Poorly characterized; dipeptides are cleared rapidly from circulation, though tissue effects are proposed to outlast detectable plasma levels.
Routes
Intranasal, Subcutaneous, Intramuscular, Oral (Russian commercial formulation)
Category
Immune & Mitochondrial
Researched benefits
What it's studied for
Immune system modulation
Russian immunology literature describes improved T-helper:T-suppressor ratios, increased absolute lymphocyte counts, and enhanced antigen-specific T-cell responses after Thymogen administration, consistent with its registered role in cellular immunodeficiency states.
Thymic function support
As a short peptide derived from thymus tissue, Thymogen is proposed to signal to T-cell progenitors and thymic epithelial cells, supporting T-cell maturation in states of age-related thymic involution or acquired immunodeficiency.
Enhanced T-cell immunity
Thymogen is claimed to modulate CD4+ and CD8+ T-cells, influencing proliferation, cytokine production (IL-2, IFN-gamma), and effector function, consistent with Th1 modulation and improved cell-mediated immunity.
Respiratory infection prevention
Decades of Russian pharmaceutical use support Thymogen as adjunctive therapy for acute respiratory infections, with modest reductions in infection frequency and severity, particularly via intranasal courses during cold/flu season.
Immune anti-aging / immunosenescence support
Within the Khavinson framework, Thymogen targets the immunosenescence layer of aging by supporting thymus-dependent immune competence that declines after thymic involution, though effects on biological age markers are not well characterized.
NK cell activity modulation
Some Russian studies describe increased natural killer cell cytotoxicity and responsiveness after Thymogen therapy, supporting broader innate and cell-mediated immune function.
Mechanism
How it works
Thymogen's proposed mechanism sits within the biology of thymic peptide immunomodulators. The thymus is the primary organ of T-cell maturation, where bone-marrow-derived progenitors undergo positive and negative selection to become naive T-cells. Because the thymus involutes dramatically after puberty, reducing T-cell diversity and increasing infection susceptibility with age, thymus-derived peptides have long been studied as a way to restore thymus-dependent immune competence.
As one of the active short-peptide components isolated from the Thymalin thymus extract, Thymogen is proposed to retain the ability to signal to T-cell progenitors and mature T-cells. Russian literature reports improvements in T-helper:T-suppressor ratios, increases in absolute lymphocyte counts, and enhanced antigen-specific responses, along with effects on the thymic microenvironment (epithelial 'nurse cells') and modulation of Th1 cytokines such as IL-2 and IFN-gamma. Some studies also describe increased NK cell cytotoxicity.
Per the broader Khavinson short-peptide bioregulator theory, Thymogen may enter cells and modulate gene expression in T-cells and thymic epithelial cells through direct DNA binding or epigenetic effects — a 'pulsed signal triggering durable gene expression' framework that is consistent with the observation that tissue effects appear to persist beyond detectable plasma levels. This gene-expression mechanism is more speculative and has limited independent validation.
Unlike thymosin alpha-1 (a 28-amino-acid peptide) or thymulin (a Zn-dependent nonapeptide), Thymogen is a simple dipeptide with no well-defined single receptor, so the 'specific receptor' hypothesis is considered implausible for such a short sequence. Its activity is proposed to derive from general signaling properties, possibly involving downstream effects of glutamate or tryptophan signaling combined with bioregulator effects. Its mechanism is less rigorously characterized than its Western thymic-peptide counterparts.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Supplied as lyophilized powder (commonly 1 mg, 5 mg, or 10 mg vials); Russian commercial product may come as pre-formulated nasal drops or injectable solution. Reconstitute with bacteriostatic water (0.9% benzyl alcohol; ~30-day refrigerated stability) or sterile water (24–48 hour stability). For a 1 mg vial, add 1 mL bacteriostatic water to yield 1 mg/mL (100 mcg per 0.1 mL = 10 units on an insulin syringe). Inject water down the vial wall, swirl gently 30–60 seconds (do not shake), confirm a clear solution, label with date/concentration, and refrigerate at 2–8°C. For intranasal use, transfer to a pharmacy-grade metered nasal spray bottle (~0.1 mL / ~100 mcg per spray at 1 mg/mL).
Beginner (intranasal)
- Dose
- 50–100 mcg per nostril
- Frequency
- Once daily
- Timing
- Morning, or as needed at first sign of illness
- Duration
- 10-day cycle; 2–4 cycles per year
- Route
- Intranasal drops or spray
Most accessible, needle-free route; preferred first approach for URI prevention. Wait 60–90 days between cycles.
Beginner (subcutaneous)
- Dose
- 100 mcg per day
- Frequency
- Once daily
- Timing
- Morning, consistent time of day
- Duration
- 10-day cycle; 2–4 cycles per year
- Route
- Subcutaneous injection
Doses are lower than most peptides. Rotate injection sites. Start with a single cycle before repeating.
Intermediate
- Dose
- Intranasal 100–200 mcg per nostril, 1–2x daily; or SC 100 mcg daily
- Frequency
- Daily during active cycle
- Timing
- Morning (SC); morning or split (intranasal)
- Duration
- 10–20 days per cycle; 4–6 cycles per year
- Route
- Intranasal and/or subcutaneous
Elevation of SC dose above 100 mcg is generally not recommended due to threshold (rather than dose-response) behavior. Combine intranasal for URI coverage with quarterly SC cycles for systemic support.
Advanced
- Dose
- SC 100–200 mcg daily; intranasal 200–300 mcg per nostril 2x daily
- Frequency
- Daily during active cycle
- Timing
- Morning-anchored, combined routes
- Duration
- 15–30 days per cycle; 6–8 cycles per year
- Route
- Subcutaneous + intranasal (combined)
Used within multi-peptide immune-optimization stacks with biomarker monitoring. Introduce peptides sequentially; maintain washouts and annual autoimmune/immune surveillance.
Standard Russian clinical
- Dose
- Intranasal 50–100 mcg per nostril 1–2x daily; SC or IM 100 mcg once daily; oral 100 mcg once daily
- Frequency
- 1–2x daily depending on route
- Timing
- Morning preferred for SC
- Duration
- Acute 5–10 days; preventive 10 days; chronic support 10–20 days, 2–4 cycles/year
- Route
- Intranasal / SC / IM / oral
Oral is a Russian commercial formulation optimized for absorption; DIY oral from powder is not considered effective due to proteolytic degradation.
- Thymogen appears to have threshold-type dose-response rather than linear dose-response — doubling from 100 to 200 mcg does not double the effect. Stay within the ~50–200 mcg daily range.
- Use pulsed dosing with 60–90 day washouts between cycles; the pulsed convention is believed to contribute to the favorable safety record and is part of the protocol, not optional.
- Prefer intranasal for URI prevention and local mucosal support; prefer subcutaneous (or intramuscular) for systemic immunomodulation.
- Effects are typically subtle — the main benefit is reduced infection frequency/severity over the 1–3 months following a cycle rather than an acute 'feel-it' effect.
- Some protocols start Thymogen ~1 week before vaccination and continue afterward to enhance response.
- Source from reputable suppliers with a certificate of analysis (purity ≥98%, correct molecular weight for the Glu-Trp dipeptide ~333.3 g/mol). Russian registered pharmaceutical product is the highest-quality reference source.
- Discontinuation does not produce rebound; simply stop when appropriate.
Evidence
Research & clinical studies (2)
Khavinson & Anisimov — theoretical framework and review of Thymogen short-peptide bioregulators
Describes the short-peptide bioregulator framework and cites multiple Russian preclinical and clinical studies of Thymogen's T-cell and immune effects.
Kuznik et al. — immune-cell-level effects of Thymogen in clinical states
Characterizes Thymogen's effects on immune cell populations across various clinical conditions.
Combinations
Stacking & blends
Dual Thymic Peptide Stack
Broad thymus-dependent immune support
Combines the defined Glu-Trp dipeptide with its parent thymus-extract peptide mixture for complementary thymic immunomodulation.
Russian + Western Thymic Combination
Enhanced cellular immunity
Pairs Thymogen with the more Western-validated 28-amino-acid thymic peptide; combined use is common and considered theoretically synergistic.
Core Khavinson Anti-Aging Stack
Immune plus general longevity/anti-aging bioregulation
Integrates thymic immune support with neural and pineal Khavinson peptides for a comprehensive short-peptide rotation.
Recovery-Focused Pairing
Immune support with tissue recovery
Adds a systemic healing/recovery peptide to Thymogen's immune modulation for post-illness or post-training use.
Immune + Anti-Inflammatory Pairing
Immune modulation with reduced inflammation
Combines T-cell support with an anti-inflammatory peptide to balance immune activation.
Comprehensive Immune Rejuvenation Stack
Intensive immunosenescence intervention
Advanced multi-thymic-peptide protocol for users with significant baseline immune concerns; peptides introduced sequentially with biomarker monitoring.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Pregnancy and lactation (limited data)
- Known hypersensitivity to Thymogen, Glu-Trp, or peptide products
- History of anaphylaxis to peptides
- Severe active autoimmune flare (rheumatoid arthritis, lupus, MS, ulcerative colitis, Crohn's, decompensated Hashimoto's)
- Organ transplant recipients on immunosuppression (immune-improving mechanism opposes transplant protection)
- Active lymphoma or leukemia without oncology oversight
- Acute T-cell-mediated reaction (severe graft-vs-host, transplant rejection)
- Severe active sepsis / septic shock (cytokine storm risk)
- Unverified product without certificate of analysis
Russian clinical practice has used Thymogen for 35+ years without major safety signals, but long-term controlled Western data does not exist. The main theoretical concern is that T-cell-enhancing effects could worsen autoimmune processes, so users with autoimmune markers should monitor carefully. Theoretical drug antagonism exists with corticosteroids, cyclosporine, tacrolimus, mycophenolate, and biologics; coordinate with a specialist if on immune-modulating pharmacotherapy. Never substitute Thymogen for appropriate antimicrobial therapy. Pulsed dosing with washouts limits cumulative exposure; annual immune and autoimmune surveillance is prudent for long-term users.
FAQ
Thymogen — common questions
Is Thymogen the same as Thymalin or Thymosin?
They are related but distinct. Thymalin is the original Russian extract from bovine thymus — a mixture of peptides. Thymogen is the synthetic dipeptide (Glu-Trp) identified as one of Thymalin's active short-peptide components. Thymosin alpha-1 is a 28-amino-acid Western-developed thymic peptide (Zadaxin), FDA-approved in some jurisdictions for hepatitis B and as adjunctive immunotherapy. All three are thymus-derived immune modulators but chemically distinct; Thymogen is the smallest and simplest.
Is Thymogen effective for preventing colds and flu?
Russian clinical literature and decades of registered use support Thymogen as adjunctive therapy for acute respiratory infections, including prevention in high-exposure contexts. The standard convention is intranasal 100 mcg per nostril daily for 10-day courses at the start of cold/flu season. Effects are typically modest — fewer or milder infections — rather than dramatic prevention. Foundational measures (vitamin D, zinc, sleep, vaccines) remain more reliable for most healthy adults.
How is Thymogen dosed?
Standard doses are 50–100 mcg per nostril intranasally 1–2x daily, or 100 mcg subcutaneously once daily, for 10-day cycles repeated 2–4 times per year. The effective dose range is narrow (Thymogen shows threshold behavior, so doubling the dose does not double the effect). Start at the lower end for first cycles. Intranasal suits URI prevention; subcutaneous suits systemic immune support.
Can I use Thymogen if I have an autoimmune disease?
This is nuanced. Thymogen enhances T-cell function, which theoretically could worsen autoimmune processes. Avoid it during active autoimmune flare. For stable remission, use is possible with specialist consultation and monitoring for flare. For people with autoimmune markers but no active disease (positive ANA, thyroid antibodies), approach cautiously with periodic monitoring. Russian practice has not reported this as a significant issue, but formal outcome studies are limited.
Is Thymogen legal where I live?
In Russia it is a registered prescription pharmaceutical. In the US, EU, UK, Canada, and Australia it is not approved for human use; personal research use typically occupies a gray area while selling it as a supplement or drug is not authorized. Import may be subject to customs seizure. It is not on the WADA prohibited list as of 2026, but tested athletes should verify current status and document supply-chain purity.
How long until I notice effects?
Acute effects during a cycle are usually subtle — no dramatic 'feel-it' moment. The main benefit is downstream reduction in infection frequency and severity over the 1–3 months following a cycle. Healthy users often notice nothing during the cycle; older adults with immunosenescence or those with frequent infections may notice more benefit. It is a background immune modulator, not a stimulant or acute-performance compound.
Can I combine Thymogen with other peptides?
Yes, and combinations are common. Compatible pairings include Thymalin, Thymosin alpha-1, Vilon, Pinealon and Epitalon (core Khavinson stack), BPC-157, and KPV. Introduce one peptide at a time to attribute effects and side effects. Avoid stacking with active immunosuppressive pharmacotherapy without specialist coordination.
What is the difference between intranasal and subcutaneous Thymogen?
Intranasal (50–100 mcg per nostril) delivers Thymogen to the nasal mucosa, avoids needles, and suits URI prevention and local immune support. Subcutaneous (100 mcg) delivers systemic immunomodulation and is the standard Russian clinical route. Advanced users sometimes combine both — intranasal daily for URI coverage plus quarterly subcutaneous cycles. Intranasal is the easier starting point for beginners.
